Can novel therapeutics halt the amyloid cascade?

Alzheimer's Research and Therapy

Volumn 2, Issue 2, 2010, Pages

  Prins, Niels D ^a   Visser, Pieter Jelle ^a,b   Scheltens, Philip ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; BAPINEUZUMAB; GAMMA SECRETASE; TARENFLURBIL;

ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; AMNESIA; ANEMIA; ASSOCIATION CORTEX; ASTROCYTE; BRAIN EDEMA; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COGNITION; COHORT ANALYSIS; DAILY LIFE ACTIVITY; DISABILITY; DIZZINESS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FUNCTIONAL STATUS; GENOTYPE; HETEROZYGOTE; HUMAN; IMMUNOTHERAPY; INFECTION; LEARNING; LIMBIC CORTEX; MICROGLIA; MINI MENTAL STATE EXAMINATION; NEUROFIBRILLARY TANGLE; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; PASSIVE IMMUNIZATION; PATHOGENESIS; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN METABOLISM; RATING SCALE; TREATMENT OUTCOME; VASOGENIC EDEMA;

EID: 77953467581     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/alzrt28     Document Type: Note

References (15)

1. Treatment of Alzheimer's disease: current status and new perspectives. E Scarpini P Scheltens H Feldman, Lancet Neurol 2003 2 539 547 10.1016/S1474-4422(03)00502-7 12941576 (Pubitemid 36994993)
2. The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J Hardy, J Neurochem 2009 110 1129 1134 10.1111/j.1471-4159.2009.06181.x 19457065
3. Alzheimer disease: mechanistic understanding predicts novel therapies. DJ Selkoe, Ann Intern Med 2004 140 627 638 15096334
4. Clinical effects of A immunization (AN1792) in patients with AD in an interrupted trial. S Gilman M Koller RS Black L Jenkins SG Griffith NC Fox L Eisner L Kirby MB Rovira F Forette JM Orgogozo, Neurology 2005 64 1553 1562 10.1212/01.WNL.0000159740.16984.3C 15883316 (Pubitemid 40617691)
5. Potential treatment opportunities for Alzheimer's disease through inhibition of secretases and A immunization. D Schenk D Games P Seubert, J Mol Neurosci 2001 17 259 267 10.1385/JMN:17:2:259 11816797 (Pubitemid 33063528)
6. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. F Bard C Cannon R Barbour RL Burke D Games H Grajeda T Guido K Hu J Huang K Johnson-Wood K Khan D Kholodenko M Lee I Lieberburg R Motter M Nguyen F Soriano N Vasquez K Weiss B Welch P Seubert D Schenk T Yednock, Nat Med 2000 6 916 919 10.1038/78682 10932230 (Pubitemid 30644751)
7. Immunization reverses memory deficits without reducing brain A burden in Alzheimer's disease model. JC Dodart KR Bales KS Gannon SJ Greene RB DeMattos C Mathis CA DeLong S Wu X Wu DM Holtzman SM Paul, Nat Neurosci 2002 5 452 457 11941374 (Pubitemid 34454251)
8. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. S Salloway R Sperling S Gilman NC Fox K Blennow M Raskind M Sabbagh LS Honig R Doody CH van Dyck R Mulnard J Barakos KM Gregg E Liu I Lieberburg D Schenk R Black M Grundman, Neurology 2009 73 2061 2070 10.1212/WNL.0b013e3181c67808 19923550
9. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. JO Rinne DJ Brooks MN Rossor NC Fox R Bullock WE Klunk CA Mathis K Blennow J Barakos AA Okello S Rodriguez Martinez de Liano E Liu M Koller KM Gregg D Schenk R Black M Grundman, Lancet Neurol 2010 9 363 372 10.1016/S1474-4422(10)70043-0 20189881
10. Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. T Kukar S Prescott JL Eriksen V Holloway MP Murphy EH Koo TE Golde MM Nicolle, BMC Neurosci 2007 8 54 10.1186/1471-2202-8-54 17650315 (Pubitemid 47261345)
11. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. GK Wilcock SE Black SB Hendrix KH Zavitz EA Swabb MA Laughlin, Lancet Neurol 2008 7 483 493 10.1016/S1474-4422(08)70090-5 18450517
12. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. RC Green LS Schneider DA Amato AP Beelen G Wilcock EA Swabb KH Zavitz, JAMA 2009 302 2557 2564 10.1001/jama.2009.1866 20009055
13. CSF biomarkers in Alzheimer's disease and controls: associations with APOE genotype are modified by age. MI Kester MA Blankenstein FH Bouwman EJ van Elk P Scheltens WM van der Flier, J Alzheimers Dis 2009 16 601 617 19276554
14. The effect of APOE genotype on clinical phenotype in Alzheimer's disease. WM Van der Flier SNM Schoonenboom YAL Pijnenburg NC Fox P Scheltens, Neurology 2006 67 526 527 10.1212/01.wnl.0000228222.17111.2a 16894123 (Pubitemid 44214991)
15. White matter lesions are associated with progression of medial temporal lobe atrophy in Alzheimer disease. F-E De Leeuw E Korf F Barkhof P Scheltens, Stroke 2006 37 2248 2252 10.1161/01.STR.0000236555.87674.e1 16902173 (Pubitemid 44337164)